ArticleThe Journal of infection2022
Risk factors for Coronavirus disease-associated mucormycosis.
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Physio-metabolic and clinical consequences of wearing face masks-Systematic review with meta-analysis and comprehensive evaluation.Frontiers in public health · 2023Pooled it
- Brazilian task force for the management of mucormycosis.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Odontogenic-onset mucormycosis: A case series from a tertiary care institute in North India.Medical mycology case reports · 2025Article
- Risk factors for COVID-19-associated mucormycosis (CAM): A case-control study.Journal of family medicine and primary care · 2025Article
- Article
- Evaluation of the Imaging Characteristics of Rhino-Orbital Cerebral Mucormycosis.World journal of plastic surgery · 2025Article
- Assessing the mask-wearing habit as a contributing factor for COVID-19-associated mucormycosis.Journal of family medicine and primary care · 2024Article
- Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study.BMC infectious diseases · 2024Observational
- Genetic Basis for Mucormycosis Progression in COVID-19 Patients: From Susceptibility to Severity.Infectious diseases & immunity · 2024Review
- A Comparative Study of Acute Invasive Fungal Sinusitis During the First and Second Waves of the COVID-19 Pandemic.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- The bacterial burden of worn face masks-observational research and literature review.Frontiers in public health · 2024Review
- Article
- Article
- Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies.Journal of fungi (Basel, Switzerland) · 2023Review
- Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports.Journal of fungi (Basel, Switzerland) · 2023Article
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Microbiology Profile of COVID-19-Associated Rhino-Orbital Mucormycosis Pathogens in South India.The American journal of tropical medicine and hygiene · 2023Article
- Multicenter Case-Control Study of COVID-19-Associated Mucormycosis Outbreak, India.Emerging infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies.
methodsWe performed a case-control study comparing cases diagnosed with CAM and taking controls as recovered COVID 19 patients who did not develop mucormycosis. Information on comorbidities, glycemic control, and practices related to COVID-19 prevention and treatment was recorded. Multivariate regression analysis was used to identify independent predictors.
resultsA total of 352 patients (152 cases and 200 controls) diagnosed with COVID-19 during April-May 2021 were included. In the CAM group, symptoms of mucormycosis began a mean of 18.9 (SD 9.1) days after onset of COVID-19, and predominantly rhino-sinus and orbital involvement was present. All, but one, CAM cases had conventional risk factors of diabetes and steroid use. On multivariable regression, increased odds of CAM were associated with the presence of diabetes (adjusted OR 3.5, 95% CI 1.1-11), use of systemic steroids (aOR 7.7, 95% CI 2.4-24.7), prolonged use of cloth and surgical masks (vs. no mask, aOR 6.9, 95%CI 1.5-33.1), and repeated nasopharyngeal swab testing during the COVID-19 illness (aOR 1.6, 95% CI 1.2-2.2). Zinc therapy was found to be protective (aOR 0.05, 95%CI 0.01-0.19). Notably, the requirement of oxygen supplementation or hospitalization did not affect the risk of CAM.
conclusionJudicious use of steroids and stringent glycemic control are vital to preventing mucormycosis. Use of clean masks, preference for N95 masks if available, and minimizing swab testing after the diagnosis of COVID-19 may further reduce the incidence of CAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.